앱클론

암을 정복한다

보물선88 조회219

새벽에 발표되었네요

축하

https://www.prnewswire.com/news-releases/promising-efficacy-of-at101-car-t-for-blood-cancer-301797434.html

For medium dose, although the dosage administered to patients is lower than that of currently available CAR-T therapies, all three patients achieved complete response (CR) four weeks after administration. Even at 5-fold lower dosage to medium dose, CR was observed in 3 out of 6 patients and partial response (PR) was observed in 2 patients. Cytokine release syndrome (CRS) and neurotoxicity (ICANS), which appear as side effects of CAR-T therapy, were also observed at low levels of 11.1% and 22.2%. In particular, the rate of 3 or higher grade on side effects was 11.1%, showing encouraging signs with regard to safety. Clinical trial of high dosage level is currently in progress.

9명 중에 6명 완전관해, 2명 부분관해 - 기존 CAR-T 대비 우월

- ORR 89%, 완전관해율 67%

- 저용량 6명 중 3명 완전관해, 2명 부분관해

- 중용량 3명 중 3명 완전관해

- 고용량 진행 중